Revenue
2019
2020
2022
2023
2024
2025
Bone Biologics Corp (BBLG)
Price$0.5684Cached quote
Net income
2008
2009
2010
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
Total cash / debt
CashTotal debt
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 · Dec 31 | 2013 · Oct 31 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | $1.07B | $1.07B | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $1.1M | $2.1M | $6.9M | $1.6M | $82,044 | $340,672 | $1.1M | $104,490 | $1.4M | $10.2M | $3.7M | $623,522 | $188,236 | — | — | — | — | — | — |
| Operating expenses | $3.2M | $4.2M | $9.4M | $3.7M | $1.1M | $825,014 | $2.4M | $2.8M | $2.6M | $20.4M | $12.0M | $3.0M | $671,985 | $4,806 | $5,231 | $4,520 | $3,472 | — | — |
| Operating income | −$3.2M | −$4.2M | −$9.4M | −$3.7M | −$1.1M | −$825,014 | −$2.4M | −$2.8M | −$2.6M | −$20.4M | −$12.0M | −$3.0M | −$671,985 | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −0.08% | −0.23% | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$3.2M | −$4.2M | −$9.4M | −$3.7M | — | — | −$2.4M | −$2.8M | −$2.6M | −$20.4M | −$12.0M | −$3.0M | — | — | — | — | — | — | — |
| EBITDA margin | — | — | — | — | — | — | −0.23% | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$3.1M | −$4.1M | −$8.9M | −$1.5M | −$1.6M | −$1.8M | −$3.4M | −$4.4M | −$7.1M | −$25.9M | −$13.9M | −$4.4M | −$1.1M | −$5,206 | −$5,631 | −$4,920 | −$3,597 | −$10,285 | −$13,343 |
| Net profit margin | — | — | — | — | — | −0.17% | −0.32% | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$2.65 | -$28.96 | -$204.06 | -$186.90 | -$504.00 | -$907.20 | -$676.80 | -$1,267.20 | -$2,606.40 | -$9,936.00 | -$7,056.00 | -$4,320.00 | -$1,440.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Diluted EPSper diluted share | -$2.65 | -$28.96 | -$204.06 | -$186.90 | -$504.00 | -$907.20 | -$676.80 | -$1,267.20 | -$2,606.40 | -$9,936.00 | -$7,056.00 | -$4,320.00 | -$1,440.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
Owners
Reported shareholders
1.32%of listed shares
CITADEL ADVISORS LLC23.88K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
CITADEL ADVISORS LLC | 1.32%23.88K shares |
Tower Research Capital LLC (TRC) | 0.11%1.95K shares |
Frelick Jeff | ≈0.02%360 shares |
Walsh Deina H | ≈0.02%313 shares |
SBI Securities Co., Ltd. | 0.01%230 shares |
Percentages use 1.81M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data